Company Overview and News
SANTA MONICA, Calif. and TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC, The Tinley Beverage Company (CSE:TNY) (OTC:TNYBF) ('Tinley" or the “Company') wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
TNYBF QRSRF TNY
2018-09-21 seekingalpha - 5
NBEV has moved up recently, mirroring the cannabis bubble hype seen on TLRY due to its proposed entry into the CBD-infused beverage space.
ABRW TNYBF QRSRF ISOLF ISOLD NBEV TLRY TNY
SANTA MONICA, Calif. and TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") is pleased to announce its intention to commence an initial production batch of 2,000 bottles of TinleyTM Cocktails Flying Mule, a cannabis-infused Moscow Mule cocktail for the California market. Tinley expects the production of this initial batch will commence on or about the third week of September.
TNYBF QRSRF TNY
The Tinley Beverage Company Inc. (the “Company" or "Tinley") is pleased to announce that it has added three additional distributors and has expanded its sales and marketing resources. It is also working to expand temporary production capacity during construction of its 20,000 square foot facility in Long Beach, California.
TNYBF QRSRF TNY
SANTA MONICA, Calif. and TORONTO, June 18, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") is pleased to announce that it has appointed Curt Marvis to its board of directors. The Company has also released its cannabis margarita to a broader base of dispensaries following a successful initial commercial test.
QYOUF NEUL TNYBF QRSRF NLN TNY
SANTA MONICA, Calif. and TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") (CSE:TNY) (OTCQX:TNYBF) is pleased to announce that long-time Cott Board and Executive member Mark Benadiba, and California cannabis industry leader Ben Knight have joined the Company’s advisory board.
TNYBF COT QRSRF E ABCO BCB ETOLF TNY
SANTA MONICA, Calif. and TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") is pleased to announce that CMX Distribution has signed a definitive agreement to carry TinleyTM cannabis-infused products throughout California, and it has taken delivery of an initial batch of the Company’s first two cannabis-infused beverages.
TNYBF QRSRF TNY
2018-04-16 globenewswire - 1
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Lineage Grow Company Ltd. (the "Company" or "Lineage"), (CSE:BUDD) announces the departure of David Drutz from his role as Chief Executive Officer (CEO) and president, effective immediately. Mr. Peter Bilodeau will be assuming the role of interim CEO and president. Mr. Bilodeau is the former CEO of Lakeside Minerals Inc., whose name was changed to Lineage Grow Company Ltd.
TWMJF TNYBF EAT RLV QRSRF WEED SPLIF LAK TNY
SANTA MONICA, Calif. and TORONTO, April 04, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") (CSE:TNY) (OTCQX:TNYBF) (formerly OTC:QRSRF) is pleased to announce that it has produced an initial batch of its TinleyTM Cocktails cannabis margarita. Tinley is also pleased to announce that a leading licensed distributor has agreed in principle to carry Tinley cannabis-infused products throughout California, and it is working towards a definitive distribution agreement in time for the anticipated release of the product.
TNYBF QRSRF TNY
TORONTO, March 26, 2018 (GLOBE NEWSWIRE) -- Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV:DM) (FSE:D4G) is pleased to announce the appointment of David Posner to the board of Graph Blockchain Limited. Mr. Posner is an accomplished executive in the cannabis sector with strong public markets experience. Mr. Posner served as Chief Executive Officer and President at Nutritional High International Inc.
TNYBF EAT QRSRF SPLIF TNY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...